Targeted therapies for rare lung diseases


Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.


Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.



May 23, 2023

Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
Read more »

May 11, 2023

Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
Read more »

May 10, 2023

Avalyn Pharma Presenting at BioEquity Europe
Read more »

April 11, 2023

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
Read more »

March 30, 2023

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
Read more »

March 23, 2023

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
Read more »

November 28, 2022

Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Read more »

October 17, 2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
Read more »

October 27, 2021

Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
Read more »

May 24, 2021

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Read more »

October 16, 2020

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Read more »

April 27, 2020

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Read more »